Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects

Ann Surg. 2013 Oct;258(4):591-6; discussion 596-8. doi: 10.1097/SLA.0b013e3182a4ea46.

Abstract

Objective: Our objective was to execute a prospective cohort study to determine relationships between plasma mtDNA DAMP levels and the occurrence of systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and mortality.

Background: Mitochondrial DNA damage-associated molecular patterns (DAMPs) accumulate in the circulation after severe injury. Observations in animal models demonstrate that mtDNA DAMPs contribute to organ dysfunction; however, the link between plasma mtDNA DAMPs and outcome in severely injured human subjects has not been established.

Methods: DNA was isolated from plasma samples taken from severely injured patients at hospital days 0, 1, and 2. Real-time PCR was used to quantify selected ≈200 base pair sequences of mtDNA within the COX1, ND1, and ND6 genes, as well as from the D-Loop transcriptional regulatory region. MODS was defined as a Denver Multiple Organ Failure score of 4 or greater.

Results: MtDNA DAMPs were quantified as PCR threshold cycle number. Lower threshold cycles indicate increased mtDNA DAMP content. Patients with SIRS had significantly increased mtDNA DAMP levels in all 4 sequences examined (32.14 ± 0.90 vs 29.00 ± 1.15 for COX1, 31.90 ± 0.47 vs 30.16 ± 1.42 for ND1, 32.40 ± 0.61 vs 28.94 ± 1.13 for ND6, and 33.12 ± 0.83 vs 28.30 ± 1.14 for D-Loop). Patients who developed MODS also had elevated mtDNA DAMP levels compared with those who did not (32.57 ± 0.74 vs 27.12 ± 0.66 for COX1, 32.45 ± 0.65 vs 28.20 ± 0.73 for ND1, 32.52 ± 0.56 vs 27.60 ± 0.79 for ND6, and 32.85 ± 0.75 vs 27.86 ± 1.27 for D-Loop). Patients with above-median mtDNA DAMP levels had a significantly elevated relative risk for mortality. Four patients died secondary to severe MODS.

Conclusions: These findings comprise the first observational evidence that plasma mtDNA DAMPs is associated with the evolution of SIRS, MODS, and mortality in severely injured human subjects.

Trial registration: ClinicalTrials.gov NCT01812941.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Cohort Studies
  • Cyclooxygenase 1 / blood
  • Cyclooxygenase 1 / genetics
  • DNA, Mitochondrial / blood*
  • Female
  • Genetic Markers
  • Humans
  • Injury Severity Score
  • Male
  • Middle Aged
  • Multiple Organ Failure / blood
  • Multiple Organ Failure / diagnosis*
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / mortality
  • NADH Dehydrogenase / blood
  • NADH Dehydrogenase / genetics
  • Prognosis
  • Prospective Studies
  • Real-Time Polymerase Chain Reaction
  • Systemic Inflammatory Response Syndrome / blood
  • Systemic Inflammatory Response Syndrome / diagnosis*
  • Systemic Inflammatory Response Syndrome / etiology
  • Systemic Inflammatory Response Syndrome / mortality
  • Wounds and Injuries / blood
  • Wounds and Injuries / complications*
  • Wounds and Injuries / mortality

Substances

  • Biomarkers
  • DNA, Mitochondrial
  • Genetic Markers
  • Cyclooxygenase 1
  • PTGS1 protein, human
  • MT-ND6 protein, human
  • NADH Dehydrogenase
  • NADH dehydrogenase subunit 1, human

Associated data

  • ClinicalTrials.gov/NCT01812941